載入...
Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder
BACKGROUND: Vortioxetine was approved by the U.S. Food and Drug Administration (FDA) in September 2013 for treating major depressive disorder (MDD). Thus far, a number of randomized, double-blind, placebo-controlled clinical trials (RCTs) of vortioxetine have been conducted in patients with MDD. We...
Na minha lista:
| 發表在: | J Psychiatry Neurosci |
|---|---|
| Main Authors: | , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
8872147 Canada Inc.
2015
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4409435/ https://ncbi.nlm.nih.gov/pubmed/25350320 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1503/jpn.140120 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|